NCT05220605 - Nebulised BromAc in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

August 14, 2022

Study Completion Date

August 25, 2022

Conditions

COVID-19 PneumoniaBromelains Adverse ReactionAcetylcysteine Adverse ReactionMucus; PlugCOVID-19 Acute Respiratory Distress Syndrome

Interventions

DRUG

BromAc

Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.

Trial Locations (1)

2217

St George Hospital, Kogarah